tetano
Editor, Senior Moderator
Vaccine. 2019 Apr 29. pii: S0264-410X(19)30528-6. doi: 10.1016/j.vaccine.2019.04.054. [Epub ahead of print]
[h=1]Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.[/h] Bissinger T[SUP]1[/SUP], Fritsch J[SUP]2[/SUP], Mihut A[SUP]2[/SUP], Wu Y[SUP]3[/SUP], Liu X[SUP]3[/SUP], Genzel Y[SUP]2[/SUP], Tan WS[SUP]3[/SUP], Reichl U[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Control and prevention of rapid influenza spread among humans depend on the availability of efficient and safe seasonal and pandemic vaccines, made primarily from inactivated influenza virus particles. Current influenza virus production processes rely heavily on embryonated chicken eggs or on cell culture as substrate for virus propagation. Today's efforts towards process intensification in animal cell culture could innovate viral vaccine manufacturing using high-yield suspension cells in high cell density perfusion processes. In this work, we present a MDCK cell line adapted to grow as single cell suspension with a doubling time of less than 20 h, achieving cell concentrations over 1 ? 10[SUP]7[/SUP] cells/mL in batch mode. Influenza A virus titer obtained in batch infections were 3.6 log[SUB]10[/SUB](HAU/100 ?L) for total- and 10[SUP]9[/SUP] virions/mL for infectious virus particles (TCID[SUB]50[/SUB]), respectively. In semi-perfusion mode concentrations up to 6 ? 10[SUP]7[/SUP] cells/mL, accumulated virus titer of 4.5 log[SUB]10[/SUB](HAU/100 ?L) and infectious titer of almost 10[SUP]10[/SUP] virions/mL (TCID[SUB]50[/SUB]) were possible. This exceeds results reported previously for cell culture-based influenza virus propagation by far and suggests perfusion cultures as the preferred method in viral vaccine manufacturing.
Copyright ? 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] Cell culture-based vaccine manufacturing; High cell density; Influenza A virus production; MDCK suspension; Process intensification; Semi-perfusion
PMID: 31047676 DOI: 10.1016/j.vaccine.2019.04.054
[h=1]Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.[/h] Bissinger T[SUP]1[/SUP], Fritsch J[SUP]2[/SUP], Mihut A[SUP]2[/SUP], Wu Y[SUP]3[/SUP], Liu X[SUP]3[/SUP], Genzel Y[SUP]2[/SUP], Tan WS[SUP]3[/SUP], Reichl U[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Control and prevention of rapid influenza spread among humans depend on the availability of efficient and safe seasonal and pandemic vaccines, made primarily from inactivated influenza virus particles. Current influenza virus production processes rely heavily on embryonated chicken eggs or on cell culture as substrate for virus propagation. Today's efforts towards process intensification in animal cell culture could innovate viral vaccine manufacturing using high-yield suspension cells in high cell density perfusion processes. In this work, we present a MDCK cell line adapted to grow as single cell suspension with a doubling time of less than 20 h, achieving cell concentrations over 1 ? 10[SUP]7[/SUP] cells/mL in batch mode. Influenza A virus titer obtained in batch infections were 3.6 log[SUB]10[/SUB](HAU/100 ?L) for total- and 10[SUP]9[/SUP] virions/mL for infectious virus particles (TCID[SUB]50[/SUB]), respectively. In semi-perfusion mode concentrations up to 6 ? 10[SUP]7[/SUP] cells/mL, accumulated virus titer of 4.5 log[SUB]10[/SUB](HAU/100 ?L) and infectious titer of almost 10[SUP]10[/SUP] virions/mL (TCID[SUB]50[/SUB]) were possible. This exceeds results reported previously for cell culture-based influenza virus propagation by far and suggests perfusion cultures as the preferred method in viral vaccine manufacturing.
Copyright ? 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] Cell culture-based vaccine manufacturing; High cell density; Influenza A virus production; MDCK suspension; Process intensification; Semi-perfusion
PMID: 31047676 DOI: 10.1016/j.vaccine.2019.04.054